Ceribell has launched a delirium monitoring solution on its point-of-care brain monitoring platform. The Nasdaq-listed company says it is the first and only FDA-cleared device to aid in delirium screening and monitoring, following its December 2025 clearance. The system combines seizure detection and delirium monitoring in one headband. AI algorithms continuously analyse brain activity and alert clinicians at the bedside. The launch follows a pilot across several hospitals. Delirium affects about 30% of intensive care patients and often goes unrecognised, as current checks are intermittent and subjective. The Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment of up to $2,171 per eligible Medicare case, effective October 1, 2026.

This healthtech company improves neurological care with AI. | / | Trevor Abes, The Market Link 0 Comments| 6 hours ago | + Favorites * For the vast majority of Stockhouse Publishing Ltd., artificial intelligence (AI) is little more than a source of untrustworthy answers. * The healthcare sector is putting the technology to more productive use by expediting diagnoses in conditions with high unmet needs. * CeriBell (NASDAQ:CBLL) stands out in this regard thanks to a proprietary AI platform that identifies seizures and delirium meaningfully faster than legacy technology. * Shares of CeriBell last traded at US$27.82, adding 131.26% year-over-year. For the vast majority of Stockhouse Publishing Ltd., AI and the large language models Stockhouse Publishing Ltd. access it through are little more than a source of untrustworthy answers, imprecise but usable images and soulless rendered voices untouched by the joys and sorrows of life. If Stockhouse Publishing Ltd. cast its gaze across the industrial spectrum, however, AI's utility becomes readily apparent. This article is a journalistic opinion piece written based on independent research. It is intended to inform investors and should not be taken as a recommendation or financial advice. One sector where AI is making a tangible difference is healthcare and the reason why is easily recognizable. The technology is famously capable of scanning and analyzing truly massive quantities of data in seconds, well beyond what a human or traditional software could process in a reasonable amount of time. Poor health outcomes, for their part, represent very specific data points in a sea of otherwise healthy scans and tests. Theoretically, if an AI program is trained to identify an ailment with a high unmet need, the quality of care should improve. A healthtech company putting this thesis in play is California-based CeriBell (NASDAQ:CBLL), market cap US$1.05 billion, whose FDA-approved CeriBell System, a point-of-care electroencephalography (EEG) platform, uses proprietary software and AI algorithms to rapidly diagnose neurological conditions in acute care settings, including delirium and non-convulsive seizures. According to clinical data compiled by the company on its official website - scroll down for references and citations - up to one third of neurological critical care patients are at risk of seizures, up to 92% of which are non-convulsive, making them tricky to suss out. CeriBell also found that at least 31% of ICU patients suffer from delirium, including up to 80% of mechanically ventilated patients, with standard of care assessments including the Confusion Assessment Method and the Intensive Care Delirium Screening Checklist falling short due to patient impairment and language barriers. Traditional EEG technology's approach to solving these problems is cumbersome at best, requiring an up to 30-minute setup, an up to 2-day results turnaround and the involvement of specially trained technicians and neurologists. The CeriBell System, on the other hand, validated in 51 peer-reviewed publications, was found to yield EEG results in only 5 minutes, leveraging an easy-to-use headband or headcap, a portable recorder and a cloud-based portal requiring minimal training, radically reducing clinical assessment times and the potential for patient complications. The system's differentiated value-add has led to its adoption in more than 600 hospitals as of October 2025, a trajectory that has translated into 14 consecutive quarters of revenue growth - from US$9.5 million in Q1 2023 to US$28.1 million in Q2 2026 - including a hefty gross margin, most recently registering at 92%, which is allowing the healthtech company to pursue aggressive growth through innovation, sales and new hires, all while preserving the potential for profitability with increasing scale. Looking ahead, CeriBell is guiding for US$114-117 million in 2026 revenue, up by 28-31% year-over-year, with US$189.3 million in cash and credit available to continue building operational momentum. Shares of CeriBell last traded at US$27.82, adding 131.26% year-over-year. Join the discussion: Find out what investors are saying about this healthtech company on the CeriBell Inc. Bullboard and explore the rest of Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here. + Favorites Follow STOCKHOUSE Today Featured news links. Featured company. Podcasts. HotCopper Wire #52 A big, juicy gold megamerger Play Episode Forge Resources: Can Colombia Coal Revenue Fund a Yukon Gold-Copper Discovery? Forge Resources Corp. (CSE: FRG) Evolve Royalties Adds 7 Copper Royalties to Capture Exploration Upside | Evolve Royalties (CSE: EVR)

Ceribell to participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. October 28, 2026 16:05 ET | Source: Ceribell SUNNYVALE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) - CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York City. The fireside chat will take place on Wednesday, November 11, 2026, at 7:00 a.m. Pacific Standard Time / 10:00 a.m. Eastern Standard Time. Event: Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Date: Wednesday, November 11, 2026 Time: 7:00 a.m. PST / 10:00 a.m. EST A live and archived webcast of the fireside chat will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/. About CeriBell, Inc. Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel point-of-care electroencephalography ("EEG") platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence ("AI")-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and monitoring delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit https://www.ceribell.com or follow the company on LinkedIn. Investor Contact Brian Johnston Gilmartin Group [email protected]